Cholesterol and Catechism: A Conservative Reading of “What They Don’t Tell Us About Heart Disease”

Source under review: A Midwestern Doctor, “What They Don’t Tell Us About Heart Disease: Unpacking the Great Cholesterol Scam and the Dangers of Statins,” The Forgotten Side of Medicine (Substack), 26 July 2025.

I read the Midwestern Doctor’s essay with a mixture of sympathy and suspicion. Sympathy because he takes aim at a medical culture that too often confuses target numbers with health. Suspicion because righteous anger can slide into overstatement. Still, he makes two claims that deserve serious attention: first, that the cholesterol–LDL story is weaker than advertised; second, that statins’ real-world benefits are smaller—and their harms larger—than their marketing. Let’s test both, and keep our heads.

The doctor leans heavily on rediscovered or re-analysed diet-heart trials. These do exist and they complicate the neat lecture-hall narrative. The Minnesota Coronary Experiment (1968–73), when re-evaluated with recovered data, found that replacing saturated fat with linoleic acid lowered cholesterol but did not reduce mortality; if anything, lower serum cholesterol associated with more deaths in the elderly subgroup.

Likewise, the Sydney Diet Heart Study re-analysis reported higher all-cause and cardiovascular mortality after swapping saturated fats for omega-6 linoleic acid. That finding sits poorly with public guidance that still treats “replace sat fat with seed oils” as a universal remedy.

On top of that, we have the documented sugar-industry push in the 1960s to nudge attention away from sucrose and towards fat. Kearns, Schmidt, and Glantz traced the correspondence and funding streams; it is not a conspiracy theory to say industry leaned on the scales. It happened. (PMC)

None of this proves cholesterol is irrelevant. It does show that the early nutrition edifice mixed science with politics and that parts of it wobble under modern scrutiny. If one wants a more clot-centred account of atherosclerosis, Malcolm Kendrick’s “thrombogenic” model is the readable standard: endothelial injury → clotting repair → healed clots pulled under the endothelium → layered plaque. You needn’t agree with every step to see it explains several awkward facts.

A few lines of evidence the clot-first view points to:

Red blood cells are not innocent bystanders. Their membranes are rich in free cholesterol; when plaques bleed, erythrocyte debris and haemoglobin feed necrotic cores and instability. This is not fringe—there’s a two-decade literature on intraplaque haemorrhage, erythrocyte membranes, and cholesterol crystals.

Lipoprotein(a) [Lp(a)] looks less like “LDL with a funny hat” and more like a pro-thrombotic, pro-inflammatory repair particle that dovetails with a clotting-repair mechanism. Genetic and clinical evidence now casts Lp(a) as a causal risk factor for atherosclerosis and aortic valve disease.

Kendrick’s overall thesis is not “LDL never matters”; it’s that damage to the endothelium plus impaired clot lysis explains where plaques form, why they layer, and why so many non-lipid stressors—lead exposure, particulate air pollution, chronic stress, smoking—track with events. I don’t feel obliged to canonise this view to see its usefulness. It widens the causal lens and humbles the idea that we fixed heart disease with one blood test.

Do statins save lives? In selected high-risk groups, yes: they reduce events, especially myocardial infarction. The right question is how much they extend life on average, and at what cost. A BMJ Open analysis translated trial results into “postponement of death.” Median delay was about 3.2 days in primary prevention and 4.1 days in secondary, over roughly five years of daily treatment. That figure is stark. It does not mean nobody benefits; it means the average postponement is measured in days, not months.

Against that, defenders will say “events prevented” matters more than all-cause survival, that the tool is crude, and that subgroups do better. Fair. But if we sell statins to the public as life-extenders rather than risk-modifiers, we should use plain numbers, not the relative-risk pyrotechnics that flatter small absolutes.

On harms, two points can be held at once:

Muscle symptoms: blinded trial meta-analyses from the Oxford group found most reported myalgias are not caused by statins, though a modest excess exists, mostly in the first year. Observational reports run higher, perhaps because of nocebo effects and selection. Even so, clinicians see a non-trivial minority who really can’t tolerate a given statin or dose. All of that can be true at once.

Diabetes: here the signal is clearer. Multiple analyses show increased new-onset diabetes, especially with intensive dosing. The absolute risks are small, but they exist, and they cluster in those already close to the edge metabolically. Patients should hear this in ordinary English before they sign up.

Cancer? The PROSPER trial in the elderly showed a slight excess at four years that did not persist at 10-year follow-up, so the “statins cause cancer” claim is overbroad. Keep the nuance.

One more irritant is risk calculators. For years, the pooled cohort equations have been used to anoint millions as “statin-eligible.” In real-world cohorts, those tools have overestimated five-year event risk by wide margins, which converts directly into overtreatment. Updates may improve calibration, but trust was dented.

the Midwestern Doctor is right that twentieth-century nutrition science was influenced by industry, and that cholesterol-lowering per se is not a guarantee of better outcomes. He is right that average survival gains from statins are modest, that diabetes risk is real, that muscle complaints are more complicated than “it’s all in your head,” and that environmental stressors and clot dynamics deserve more attention. Those claims are documented.

He overreaches when anecdote stands in for evidence or when sweeping lines about vaccine comparisons and malign motives are used to do the argumentative lifting. Not every null or awkward result hides in a filing cabinet. Not every panel is bought. The medical guild is flawed; it isn’t a Bond villain.

He also leans hard into toxicity language. That may match some patients’ experiences, but the best blinded evidence on muscle symptoms urges caution; many aches resolve with dose changes, drug swaps, or simply time. The ethical path is informed consent without melodrama.

The conservative instinct—in medicine as in politics—is to distrust central plans and cherish local knowledge. Apply that here:

Treat people, not target numbers. If a 65-year-old with calcified arteries, high Lp(a), and a heavy event history wants every tool going, statins fit. If a slim 45-year-old with clean calcium scoring and good fitness is pushed onto life-long pills by an over-zealous calculator, say no.

Widen the frame to endothelial health and coagulation. Cut smoking. Reduce fine-particulate exposure where you can. Sleep. Manage stress properly rather than with slogans. Don’t sneer at the clot-repair model; use it as a prompt to look upstream at damage rather than only downstream at LDL.

Tell patients the absolute numbers. “On average, statins might postpone death by a few days over five years, but they do reduce heart attacks in higher-risk groups. They can raise diabetes risk a little. Most muscle pains aren’t the drug, some are. We can try a lower dose, a different statin, or stop if you’re unlucky.” That paragraph does more for trust than a glossy leaflet.

The Midwestern Doctor has performed a service by dragging awkward evidence into daylight. I do not buy his entire indictment. I do support his central plea: stop pretending that mass medication plus a tidy lipid panel equals victory. Heart disease is a damage-and-repair saga written in the endothelium, the blood, and the life you live. Pills can help. They cannot replace truth-telling—or prudence.

Further reading & sources

A Midwestern Doctor, “What They Don’t Tell Us About Heart Disease,” 26 July 2025. (midwesterndoctor.com)

Ramsden et al., Minnesota Coronary Experiment re-evaluation, BMJ (2016). (BMJ)

Ramsden et al., Sydney Diet Heart re-evaluation, BMJ (2013). (BMJ)

Kearns et al., Sugar industry influence, JAMA Internal Medicine (2016). (JAMA Network)

Kristensen et al., “postponement of death” with statins, BMJ Open (2015). (bmjopen.bmj.com)

Preiss et al., intensive-dose statins and diabetes risk, JAMA (2011); Casula et al., meta-analysis (2017). (JAMA Network)

Reith et al., muscle symptoms in blinded trials, Lancet (2022). (The Lancet)

Rana et al., overestimation by pooled cohort equations, JACC (2016). (JACC)

Kendrick, The Clot Thickens; overviews of the thrombogenic hypothesis. (drmalcolmkendrick.org)

RBCs, intraplaque haemorrhage, and instability: Kolodgie et al., NEJM (2003); Jeney et al., Arterioscler Thromb Vasc Biol; Mekke et al., Sci Rep (2023). (New England Journal of Medicine)

Lp(a) as causal risk factor: Reyes-Soffer et al., Arteriosclerosis, Thrombosis, and Vascular Biology (2022); Kronenberg et al., European Heart Journal (2022). (AHA Journals)